Pharmerit International, Rotterdam, The Netherlands.
Value Evidence and Outcomes, GlaxoSmithKline plc., Brentford, UK.
BMC Pulm Med. 2020 Apr 3;20(1):79. doi: 10.1186/s12890-020-1090-5.
The Asthma Control Test (ACT) has been used to assess asthma control in both clinical trials and clinical practice. However, the relationships between ACT score and other measures of asthma impact are not fully understood. Here, we evaluate how ACT scores relate to other clinical, patient-reported, or economic asthma outcomes.
A targeted literature search of online databases and conference abstracts was performed. Data were extracted from articles reporting ACT score alongside one or more of: Asthma Control Questionnaire (ACQ) score; rescue medication use; exacerbations; lung function; health-/asthma-related quality of life (QoL); sleep quality; work and productivity; and healthcare resource use (HRU) and costs.
A total of 1653 publications were identified, 74 of which were included in the final analysis. Of these, 69 studies found that improvement in ACT score was related to improvement in outcome(s), either as correlation or by association. The level of evidence for each relationship differed widely between outcomes: substantial evidence was identified for relationships between ACT score and ACQ score, lung function, and asthma-related QoL; moderate evidence was obtained for relationships between ACT score and rescue medication use, exacerbations, sleep quality, and work and productivity; limited evidence was identified for relationships between ACT score and general health-related QoL, HRU, and healthcare costs.
Findings of this review suggest that the ACT is an appropriate measure for overall asthma impact and support its use in clinical trial settings. GlaxoSmithKline plc. study number HO-17-18170.
哮喘控制测试(ACT)已被用于评估临床试验和临床实践中的哮喘控制情况。然而,ACT 评分与其他哮喘影响衡量标准之间的关系尚未完全明确。在这里,我们评估了 ACT 评分与其他临床、患者报告或经济哮喘结果之间的关系。
对在线数据库和会议摘要进行了有针对性的文献检索。从报告 ACT 评分以及以下一种或多种指标的文章中提取数据:哮喘控制问卷(ACQ)评分;急救药物使用;恶化;肺功能;健康/哮喘相关生活质量(QoL);睡眠质量;工作和生产力;以及医疗资源使用(HRU)和成本。
共确定了 1653 篇出版物,其中 74 篇被纳入最终分析。其中,69 项研究发现 ACT 评分的改善与结果的改善相关,无论是相关性还是关联性。每个结果之间的证据水平差异很大:ACT 评分与 ACQ 评分、肺功能和哮喘相关 QoL 之间的关系具有充分证据;ACT 评分与急救药物使用、恶化、睡眠质量和工作和生产力之间的关系具有中等证据;ACT 评分与一般健康相关 QoL、HRU 和医疗保健成本之间的关系具有有限证据。
本综述的结果表明,ACT 是衡量整体哮喘影响的适当指标,并支持其在临床试验环境中的使用。葛兰素史克公司。研究编号 HO-17-18170。